Literature DB >> 11163680

Protective immunity against herpes simplex virus generated by DNA vaccination compared to natural infection.

P H Nass1, K L Elkins, J P Weir.   

Abstract

To evaluate the utility of plasmid DNA vaccination against disease caused by herpes simplex virus (HSV), we compared the strength of protection against lethal challenge following natural virus infection with that following vaccination with a plasmid encoding HSV glycoprotein gD (gD-DNA). We further determined the cellular basis of each type of protection using lymphocyte deficient knockout mice. Establishment of immunity to HSV using live virus immunization required CD8+ T cells and B cells, but not CD4+ or gamma/delta+ T cells, and was related to specific antibody levels; surprisingly, CD4 knockout mice had large quantities of IgG anti-HSV serum antibodies. Establishment of immunity to HSV using gD-DNA immunization approached the strength of that generated following sublethal infection, but was dependent on alpha/beta+ CD4+ T cells, CD8+ T cells, B cells, and even partially on gamma/delta+ T cells, and not strictly correlated with antibody levels.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11163680     DOI: 10.1016/s0264-410x(00)00380-7

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  9 in total

1.  Immunization with a vaccine combining herpes simplex virus 2 (HSV-2) glycoprotein C (gC) and gD subunits improves the protection of dorsal root ganglia in mice and reduces the frequency of recurrent vaginal shedding of HSV-2 DNA in guinea pigs compared to immunization with gD alone.

Authors:  Sita Awasthi; John M Lubinski; Carolyn E Shaw; Shana M Barrett; Michael Cai; Fushan Wang; Michael Betts; Susan Kingsley; Daniel J Distefano; John W Balliet; Jessica A Flynn; Danilo R Casimiro; Janine T Bryan; Harvey M Friedman
Journal:  J Virol       Date:  2011-08-03       Impact factor: 5.103

2.  Comparative efficacy and immunogenicity of replication-defective, recombinant glycoprotein, and DNA vaccines for herpes simplex virus 2 infections in mice and guinea pigs.

Authors:  Yo Hoshino; Sarat K Dalai; Kening Wang; Lesley Pesnicak; Tsz Y Lau; David M Knipe; Jeffrey I Cohen; Stephen E Straus
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

3.  A DNA vaccine-encoded nucleoprotein of influenza virus fails to induce cellular immune responses in a diabetic mouse model.

Authors:  Abbas Jamali; Farzaneh Sabahi; Taravat Bamdad; Hamidreza Hashemi; Fereidoun Mahboudi; Masume Tavasoti Kheiri
Journal:  Clin Vaccine Immunol       Date:  2010-02-17

4.  Immunization with HSV-1 glycoprotein C prevents immune evasion from complement and enhances the efficacy of an HSV-1 glycoprotein D subunit vaccine.

Authors:  Sita Awasthi; John M Lubinski; Harvey M Friedman
Journal:  Vaccine       Date:  2009-09-15       Impact factor: 3.641

Review 5.  Developments in herpes simplex virus vaccines: old problems and new challenges.

Authors:  J Rajcáni; V Durmanová
Journal:  Folia Microbiol (Praha)       Date:  2006       Impact factor: 2.629

6.  Direct application of plasmid DNA containing type I interferon transgenes to vaginal mucosa inhibits HSV-2 mediated mortality.

Authors:  Bobbie Ann Austin; Cassandra M James; Peter Härle; Daniel J J Carr
Journal:  Biol Proced Online       Date:  2006-06-14       Impact factor: 3.244

7.  Immune responses in Balb/c mice induced by a candidate SARS-CoV inactivated vaccine prepared from F69 strain.

Authors:  Chuan-hai Zhang; Jia-hai Lu; Yi-fei Wang; Huan-ying Zheng; Sheng Xiong; Mei-ying Zhang; Xin-jian Liu; Jiu-xiang Li; Zhuo-yue Wan; Xin-ge Yan; Shu-Yuan Qi; Zhiyong Cui; Biliang Zhang
Journal:  Vaccine       Date:  2005-05-02       Impact factor: 3.641

Review 8.  Antiviral reactivities of gammadelta T cells.

Authors:  Fabrizio Poccia; Chiara Agrati; Federico Martini; Maria Rosaria Capobianchi; Marianne Wallace; Miroslav Malkovsky
Journal:  Microbes Infect       Date:  2005-03-03       Impact factor: 2.700

9.  Immune response and cytokine production following immunization with experimental herpes simplex virus 1 (HSV-1) vaccines.

Authors:  V Durmanová; M Sapák; J Kosovský; I Rezuchová; M Kúdelová; M Buc; J Rajcáni
Journal:  Folia Microbiol (Praha)       Date:  2008-05-15       Impact factor: 2.629

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.